Key facts
- This page summarizes Albert D. Dyrness's Form 4 filing for Sonnet BioTherapeutics Holdings, Inc. (SONN).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 03 Dec 2025, 21:12.
Albert D. Dyrness - 02 Dec 2025 Form 4 Insider Report for Sonnet BioTherapeutics Holdings, Inc. (SONN)
- Reporting relationship
- Director
- Issuer ticker
- SONN
- Reported as of
- 02 Dec 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Dec 2025, 21:12:31 UTC
- Prior SEC filing
- 15 Jul 2025
- Next SEC filing
- 11 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Albert D. Dyrness
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Albert D. Dyrness filed Form 4 for Sonnet BioTherapeutics Holdings, Inc. (SONN) on 03 Dec 2025.
Change
- Previous filing in this sequence was filed on 15 Jul 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001664801
Primary reporting owner
Dyrness Albert D.
- Relationship
- Director
- Address
- 100 OVERLOOK CENTER, SUITE 102, PRINCETON
- Signature
- /s/ Albert D. Dyrness
- Signature date
- 03 Dec 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SONN
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -4,537
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 02 Dec 2025
- Ownership
- Direct
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Albert D. Dyrness is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
On December 2, 2025, pursuant to the Business Combination Agreement (the "BCA"), dated July 11, 2025, by and among Sonnet BioTherapeutics Holdings, Inc. (the "Company"), Rorschach I LLC ("Rorschach"), Hyperliquid Strategies Inc ("HSI"), TBS Merger Sub Inc ("Company Merger Sub") and Rorschach Merger Sub, LLC ("Rorschach Merger Sub"), Rorschach Merger Sub merged with and into Rorschach with Rorschach surviving the merger as a direct wholly owned subsidiary of HSI and immediately following such merger, Company Merger Sub merged with and into the Company with the Company surviving the merger as a direct wholly owned subsidiary of HSI (the "Company Merger").
Footnote F2
(Continued from footnote 1) Includes (i) 4,000 restricted stock units granted on July 11, 2025 which, as a result of the Company Merger, vested at the Effective Time and (ii) 537 vested restricted stock units held by the Reporting Person at the Effective Time. Pursuant to the BCA, each restricted stock unit was exchanged at the Effective Time for (i) one-fifth of a share of HSI Common Stock and (ii) one CVR.
Footnote F3
All amounts reflect the Company's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024.